Various clinical symptoms precede the diagnosis of multiple sclerosis by several years.
High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.
The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.
There is a linear correlation for physical activity with amyotrophic lateral sclerosis.
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.
ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.
Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.
The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.
Neurology Advisor speaks with Annabelle Baughan, a retired hematologist-oncologist, and discusses her personal experience with Andersen-Tawil syndrome.
A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.
Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.
Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying TherapyApril 23, 2018
The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.
Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.
Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.
A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.
As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.
Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.
Compared with consuming fish less than once per month and no supplements, high fish intake was correlated with a significantly reduced risk of multiple sclerosis.
Scoliosis surgery in patients with cerebral palsy leads to a significant improvement in health-related quality of life.
The administration of treatment was performed over 5 treatment cycles, and the investigators assessed TWSTRS changes at baseline and 4 weeks following injection.
Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.
Patients who received 100 mg/day riluzole spent significantly more time in stage 4 than patients who were randomly assigned to placebo.
Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.
Neurology Advisor spoke with Annabelle Baughan, a retired hematologist-oncologist, who shared her personal experience with Andersen-Tawil syndrome.
By inhibiting the activation of myostatin, SRK-015 may promote a clinically meaningful increase in muscle mass and strength.
The advantages of oral prednisone include "being less expensive and more convenient to access and administer and [being] preferred by patients to [intravenous] methylprednisolone."
Of the total patients, 178 (29.7%) discontinued DMT during the study period with only 1 documented relapse occurring in the discontinuers.
Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.
The study was unable to verify whether the findings may be applicable for lesion locations other than those found with brain biopsies.
Further research is warranted to clarify the role played by insulin resistance in the pathogenesis of amyotrophic lateral sclerosis.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics